Obesity, height, and advanced prostate cancer: extending current evidence toward precision prevention.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Review of Mendelian randomization studies on common male-specific diseases.Frontiers in endocrinology · 2025
   Pooled it
2. Development and validation of multidimensional nomograms for predicting prostate cancer risk: a retrospective study.Frontiers in oncology · 2026
   Article
3. Peri-Prostatic Adipocyte-Released TGFβ Enhances Prostate Cancer Cell Motility by Upregulation of Connective Tissue Growth Factor.Biomedicines · 2021
   Article

Corrections and comments

• Comment on
  Measures of body fatness and height in early and mid-to-late adulthood and prostate cancer: risk and mortality in The Pooling Project of Prospective Studies of Diet and Cancer.2020

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as